Alex Martin is Chief Executive Officer of Palladio Biosciences. He previously served as Chief Executive Officer of Realm Therapeutics (RLM), which was acquired by ESSA Pharma (EPIX), where he now serves as a Director. Alex was also Chief Operating Officer of Intercept Pharmaceuticals (ICPT) and Chief Finance Officer of BioXell (BXLN), which was acquired by Cosmo Pharmaceuticals (COPN). Alex began his career at SmithKline Beecham Pharmaceuticals, where he held roles of increasing responsibility in marketing and business development, and later joined Novartis as Vice President, Global Business Development & Licensing. He is currently Chairman of the Board of Veralox Therapeutics, an active coach and mentor to other senior executives, and a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship, and raising capital. Alex holds a BA from Cornell University and an MBA from Harvard.